N@N

REPLIGEN CORP (NASDAQ:RGEN), Down By 4.71% ($0.18) From $3.800 After BUYINS.NET Report Predicted Weakness After Earnings

^{Published on 2011-06-09 13:23:09 - WOPRAI}
 

June 9, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, June 8th 2011 stating that REPLIGEN CORP (NASDAQ:RGEN) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=rgen&id=171267

At the time this story was written, REPLIGEN CORP (NASDAQ:RGEN) is Down By 4.71% ($0.18) From $3.800 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

REPLIGEN CORP (NASDAQ:RGEN) - Repligen Corporation, a biopharmaceutical company, engages in the development and commercialization of therapies that deliver value to patients and clinicians in neurology, gastroenterology, and orphan diseases. It sells a line of commercial bioprocessing products based on Protein A, as well as single or limited campaign use pre-packed chromatography columns, which are used in the production of monoclonal antibodies and other biopharmaceutical manufacturing applications. The company also offers intellectual property on monoclonal antibody and antibody fusion products consisting of CTLA4, a regulator of the activity of the immune system that provides a treatment for patients who are refractory to existing therapies, as well as certain autoimmune disorders, including rheumatoid arthritis; and Erbitux, a monoclonal antibody for the treatment of certain forms of colon cancer, as well as head and neck cancer. In addition, its development stage products include Secretin for MRI imaging of the pancreas; Uridine for bipolar depression; Histone Deacetylase Inhibitors for Friedreichs Ataxia; and DcpS Inhibitors for spinal muscular atrophy. Further, the company involves in the development and commercialization of products that are used for the production of biopharmaceuticals. It sells its products through value added resellers, as well as through distributors. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. REPLIGEN CORP (NASDAQ:RGEN) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net